Wedbush analyst David Nierengarten raised the firm’s price target on Disc Medicine (IRON) to $110 from $90 and keeps an Outperform rating on the shares. The firm notes the company received a Commissioner’s National Priority Voucher, reducing drug application review time for bitopertin to 1-2 months. Wedbush expects FDA to decide on Priority Review for bitopertin in EPP/XLP in late November/early December based on a September 30 NDA submission, which could imply regulatory approval by early February 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Promising Outlook for Disc Medicine: Buy Rating Backed by FDA Priority Voucher and Strategic Preparations for Bitopertin Launch
- Disc Medicine receives CNPV from FDA for Bitopertin
- Disc Medicine Board Member Mona Ashiya Resigns
- Buy Rating Affirmed for Disc Medicine Amid Promising Bitopertin Prospects in EPP Treatment
- Promising Developments and Positive Trials Support Buy Rating for Disc Medicine’s Bitopertin